
Asco 2022 – the spirit of Rova-T struggles to live on
DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.

Asco 2022 – Abbvie goes back to basics with navitoclax
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.

Abbvie to become the biggest of pharmas in 2028
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.

The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?

Investors bite the big pharma hands that feed them
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.